BioSpace News Archive

Foldax® , Inc. today announced the successful first-in-human use of its biopolymer Tria™ heart valve in surgically replacing a diseased mitral valve. The first case was performed by David Heimansohn, MD, at Ascension St. Vincent Hospital, Indianapolis, as part of a U.S. early feasibility research study.

Organicell To Present Results Of Zofin ™ Clinical Studies At The International Society Of Cell And Gene Therapy Annual Meeting

Inovalon (NASDAQ: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that it has been awarded a significant patent for its capability to aggregate healthcare data from across the healthcare ecosystem, apply requested analytics, and make the results available on demand in real time. U.S. Patent No. 11,011,256, for the “Systems and Method for Providing an On-Demand Real-Time Patient-Specific Data

Selecta Biosciences, Inc., a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference to be held June 1-4, 2021.

- Pegcetacoplan demonstrated statistical superiority on the co-primary endpoints of haemoglobin stabilisation (p<0.0001) and reduction in lactate dehydrogenase (LDH) (p<0.0001) compared to standard of care, which did not include complement inhibitors, at week 26 - Mean haemoglobin levels in the pegcetacoplan group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from 8.7 g/dL to 9.4 g/dL on standard of care (p=0.0019)

Universe Pharmaceuticals INC, a pharmaceutical producer and distributor in China, announced that the Company entered into a letter of intent on April 23, 2021 for strategic cooperation with Kitanihon Pharmaceutical Co., Ltd., a Japanese company engaged in the research, development, manufacturing, and distribution of pharmaceutical and medical products.

TRACON Pharmaceuticals announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 4, 2021 at 2:30pm Eastern Time.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that the company will host a conference call and webcast to review initial data from the ongoing Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in advanced solid tumors.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, announced the appointment of Tim Kelly as chief financial officer, effective immediately.

Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, reports financial results for the first quarter that ended March 31, 2021, along with an update on the company’s key developments, business operations and upcoming milestones.